Lataa...
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma
The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...
Tallennettuna:
| Julkaisussa: | Oncogene |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501768/ https://ncbi.nlm.nih.gov/pubmed/28263969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.526 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|